Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005
- Details
- Category: Pfizer
Pfizer Inc. commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis (RA) which has been posted for the European League Against Rheumatism (EULAR) conference.
Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals is aware of two studies published in The British Medical Journal. These papers are "Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database" by Lianne Parkin et al (1); and
Lundbeck's partner Mochida receives approval of Lexapro in Japan
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announced that Mochida Pharmaceutical Co., Ltd. (Mochida) has obtained approval of Lexapro® 10 mg (escitalopram) from the Japanese Ministry of Health, Labour and Welfare (MHLW).
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS) of $1.34 for the first quarter of 2011, an increase of 3 percent compared to $1.30 for the first quarter of 2010. Adjusted net income decreased 2 percent to $1,258 million in the first quarter of 2011 compared to $1,282 million in the first quarter of 2010.
Abbott Reports 17.4 Percent Sales Growth
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced financial results for the first quarter ended March 31, 2011. Worldwide sales increased 17.4 percent to more than $9 billion, including a favorable 1.3 percent effect of foreign exchange, which was driven by double-digit growth in each of Abbott's three major business categories.
Novartis makes strong start for the year
- Details
- Category: Novartis
Novartis' net sales rose 16% (+14% cc) to USD 14.0 billion. Currency benefited sales by 2% as the dollar weakened against most currencies. Excluding A(H1N1) pandemic flu vaccine sales and Alcon, net sales grew 10% (+8% cc).
More Pharma News ...
- GSK welcomes key agreement to support global preparedness against pandemic influenza
- Roche Group's first-quarter 2011 sales on track for full-year targets
- Pfizer Announces Top-Line Results of Third Phase 3 Clinical Trial of Tofacitinib (CP-690,550)
- Bayer's Rivaroxaban Submitted for Approval in Japan
- Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
- Forest Laboratories Completes Acquisition of Clinical Data, Inc.
- Nycomed acquires distribution rights to product portfolio in Turkey